SG Americas Securities’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-21,828
| Closed | -$439K | – | 3525 |
|
|
2026
Q1 | $439K | Sell |
21,828
-26,202
| -55% | -$422K | ﹤0.01% | 2249 |
|
|
2025
Q4 | $776K | Buy |
48,030
+6,410
| +15% | +$84.9K | ﹤0.01% | 2211 |
|
|
2025
Q3 | $507K | Buy |
+41,620
| New | +$575K | ﹤0.01% | 2102 |
|
|
2025
Q1 | – | Sell |
-14,508
| Closed | -$123K | – | 3607 |
|
|
2024
Q4 | $123K | Buy |
14,508
+1,319
| +10% | +$13.7K | ﹤0.01% | 2579 |
|
|
2024
Q3 | $153K | Buy |
+13,189
| New | +$166K | ﹤0.01% | 2715 |
|
|
2024
Q2 | – | Sell |
-12,082
| Closed | -$143K | – | 3074 |
|
|
2024
Q1 | $143K | Sell |
12,082
-125,735
| -91% | -$1.68M | ﹤0.01% | 2245 |
|
|
2023
Q4 | $1.69M | Buy |
137,817
+6,670
| +5% | +$60.7K | 0.02% | 756 |
|
|
2023
Q3 | $1.26M | Buy |
131,147
+9,794
| +8% | +$100K | 0.01% | 1079 |
|
|
2023
Q2 | $1.09M | Buy |
+121,353
| New | +$1.12M | 0.01% | 1012 |
|
|
2023
Q1 | – | Sell |
-15,734
| Closed | -$106K | – | 3415 |
|
|
2022
Q4 | $106K | Sell |
15,734
-823
| -5% | -$4.41K | ﹤0.01% | 2680 |
|
|
2022
Q3 | $240K | Sell |
16,557
-134
| -0.8% | -$1.87K | ﹤0.01% | 2164 |
|
|
2022
Q2 | $164K | Buy |
+16,691
| New | +$184K | ﹤0.01% | 2805 |
|
|
2022
Q1 | – | Sell |
-11,956
| Closed | -$158K | – | 3214 |
|
|
2021
Q4 | $158K | Sell |
11,956
-6,042
| -34% | -$96.2K | ﹤0.01% | 2791 |
|
|
2021
Q3 | $314K | Sell |
17,998
-5,092
| -22% | -$103K | ﹤0.01% | 2905 |
|
|
2021
Q2 | $553K | Buy |
23,090
+678
| +3% | +$17.7K | ﹤0.01% | 1891 |
|
|
2021
Q1 | $576K | Buy |
22,412
+16,936
| +309% | +$445K | ﹤0.01% | 1924 |
|
|
2020
Q4 | $104K | Buy |
+5,476
| New | +$93.9K | ﹤0.01% | 3019 |
|
|
2016
Q1 | – | Sell |
-871
| Closed | -$44K | – | 3105 |
|
|
2015
Q4 | $44K | Sell |
871
-453
| -34% | -$23.7K | ﹤0.01% | 2485 |
|
|
2015
Q3 | $66K | Buy |
+1,324
| New | +$113K | ﹤0.01% | 1938 |
|
Other funds holding KALV
SG Americas Securities's KALV Position: Q2 2026 in Review
SG Americas Securities sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 21,828 shares — an estimated $439K sold.
SG Americas Securities first reported a position in KALV in Q3 2015 and held it in 19 quarters. The position peaked at $1.69M in Q4 2023. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- SG Americas Securities reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- SG Americas Securities sold 21,828 KalVista Pharmaceuticals shares in Q2 2026, an estimated $439K.
- SG Americas Securities first reported a position in KalVista Pharmaceuticals in Q3 2015 and held it in 19 quarters.
- SG Americas Securities's KalVista Pharmaceuticals position peaked at $1.69M in Q4 2023.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.